IL32 and neoplasm: When NK4 treatment was initiated on day 10 (a time when cancer cells were already invading surrounding tissues), NK4 potently inhibited the tumor growth, peritoneal dissemination, and ascites accumulation at four weeks after the tumor inoculation.